Moclobemide (Aurorix) in primary major depression.
1. Moclobemide (Aurorix) is a newly developed, effective, short-acting well tolerable and safe antidepressant which belongs to the new class of reversible monoamine-oxidase-A inhibitors. 2. Aurorix was given per os in an open clinical trial for 6 weeks to 30 patients with DSM-III diagnoses of (nonpsychotic, nonmelancholic), major depression. 3. Out of the 25 patients who completed the study 14 (56%) were responders and 11 (44%) non-responders. 4. The patients tolerated the drug very well, and no serious side-effects were noted. 5. Pretreatment biological markers (dexamethasone suppression test, platelet-MAO-B activity, 3H-imipramine binding, thyroid function) did not have a predictive value regarding the drug response.
Rihmer
Z
Z
Department of Psychiatry No. XIII, National Institute for Psychiatry and Neurology, Budapest, Hungary.
Barsi
J
J
Vad
G
G
György
S
S
Zalay
B
B
Vég
K
K
Gábor
A
A
D000328:Adult; D000368:Aged; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers; D001714:Bipolar Disorder / Q000188:drug therapy / Q000523:psychology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D003907:Dexamethasone; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D001549:Benzamides; D015415:Biomarkers; D008996:Monoamine Oxidase Inhibitors; D003907:Dexamethasone; D020912:Moclobemide